Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)



Status:Recruiting
Conditions:Colitis, Colitis, Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:2 - 17
Updated:6/13/2018
Start Date:November 8, 2017
End Date:December 3, 2020
Contact:Takeda Study Registration Call Center
Email:medicalinformation@tpna.com
Phone:+1-877-825-3327

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and
tolerability in pediatric participants with moderately to severely active UC or CD.

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to
treat pediatric participants who have moderately to severely active UC or CD. This study will
look at the PK, efficacy, immunogenicity, safety, and tolerability in participants who take
vedolizumab.

The study will enroll approximately 80 participants. Participants will be randomly assigned
(by chance, like flipping a coin) to one of the two dose regimens (high or low) per weight
group >=30 kg and 10 kg to <30 kg in ratio 1:1—which will remain undisclosed to the
participant and study doctor during the study (unless there is an urgent medical need):

- Vedolizumab high dose group - Vedolizumab 300 mg or 200 mg

- Vedolizumab low dose group - Vedolizumab 150 mg or 100 mg

All participants will be administered vedolizumab via IV infusion. Participants assigned to
the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week
14 will receive the high dose (that is, 300 mg for participants >=30 kg baseline weight and
200 mg for participants 10 kg to <30 kg baseline weight) of vedolizumab IV at Week 14.

This multi-center trial will be conducted worldwide. The overall time to participate in this
study is up to 36 weeks. After completing the Week 22 Visit procedures, eligible participants
may enter an extension study. Participants will make multiple visits to the clinic, and those
who do not enter extension study will have a final visit 18 weeks after last dose of study
drug for a follow-up assessment. Participants who do not enter the extension study will also
participate in a long-term safety follow-up, by telephone, 6 months after the last dose of
study drug.

Inclusion Criteria:

1. Participants weighs >=10 kg at the time of randomization.

2. Has a medical history of moderately to severely active UC during Screening defined as
complete Mayo score of 6 to 12, and a total Mayo subscores of stool frequency and
rectal bleeding >=4 and Mayo endoscopy subscore >=2, or has moderately to severely
active CD defined as simple endoscopic score for Crohn's disease (SES-CD) >=7, and the
CDAI components of average daily abdominal pain score of greater than (>) 1 for the 7
days prior, and total number of liquid/very soft stools >10 within 7 days prior to
first dose of study drug.

3. Has evidence of UC extending proximal to the rectum (that is, not limited to
proctitis) or evidence of CD involving the ileum and/or colon, at a minimum.

4. Has extensive colitis or pancolitis of >8 years duration or left-sided colitis of >12
years duration must have documented evidence that a surveillance colonoscopy was
performed within 12 months prior to their first dose of study drug.

5. Has a family history of colorectal cancer (that is, first-degree relative), personal
history of increased colorectal cancer risk, or other known risk factor must be
up-to-date on colorectal cancer surveillance.

6. The participant's vaccinations are up to date.

7. Has demonstrated an inadequate response to, loss of response to, or intolerance of at
least 1 of the following agents as defined below:

Corticosteroids:

• Signs and/or symptoms of persistently active disease despite a history of at least
one 4-week induction regimen that included a dose equivalent to or more than
prednisone 1 milligram per kilogram (mg/kg) daily orally for 2 weeks or IV for 1 week.

OR

• Two failed attempts to taper corticosteroids to below a dose equivalent to
prednisone 10 mg daily orally on 2 separate occasions.

OR

• History of significant intolerance to corticosteroids (including, but not limited
to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, and
infection).

Immunomodulators:

• Signs and symptoms of persistently active disease despite a history of at least one
8-week regimen of oral azathioprine (AZA) (>=1.5 milligram per kilogram per day
[mg/kg/day]) or 6-mercaptopurine (6-MP) mg/kg (>=1.0 mg/kg/day) or methotrexate (MTX)
(>=10 milligram per square meter [mg/m^2] once a week).

OR

• History of intolerance of at least 1 immunomodulator (including, but not limited to,
nausea/vomiting, abdominal pain, pancreatitis, liver function test (LFT)
abnormalities, lymphopenia, thiopurine methyltransferase genetic mutation, infection).

Tumor necrosis factor-alpha (TNF-α) antagonists:

• Signs and symptoms of persistently active disease despite a history of at least 1
induction regimen of infliximab 5 mg/kg IV at Week 0 and Weeks 2 and 6 or adalimumab
2-week regimen of 160 mg on Day 1 and 80 mg on Day 15 if >=40 kg or 80 mg on Day 1 and
40 mg on Day 15 if <40 kg. For any other TNF-α antagonist, the participant must
demonstrate signs and symptoms of persistently active disease despite a history of at
least 1 induction regimen, as determined by the investigator.

OR

• Recurrence of symptoms during maintenance dosing following prior clinical benefit,
that is, fitting clinically with secondary loss of response (discontinuation despite
clinical benefit does not qualify).

OR

• History of intolerance of infliximab or adalimumab (including, but not limited to,
infusion-related reaction, demyelination, congestive heart failure, infection).

8. The participant may be receiving a therapeutic dose of the following drugs:

1. Oral 5-aminosalicylic acid (5-ASA) compounds, providing the dose has been stable
for the 2 weeks prior to first dose of study drug.

2. Oral corticosteroid therapy (prednisolone at a stable dose <=50 mg/day, or
equivalent steroid), provided that the dose has been stable for the 4 weeks prior
to first dose of study drug if corticosteroids have been initiated, or for the 2
weeks prior to first dose of study drug if corticosteroids are being tapered.

3. Probiotics (example, Saccharomyces boulardii), provided the dose has been stable
for the 2 weeks prior to first dose of study drug.

4. Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of
chronic diarrhea.

5. Antibiotics used for the treatment of CD (example, ciprofloxacin, metronidazole),
providing the dose has been stable for the 2 weeks prior to first dose of study
drug.

6. Azathioprine or 6-MP, provided the dose has been stable for the 8 weeks prior to
first dose of study drug.

7. Methotrexate (MTX), provided the dose has been stable for the 8 weeks prior to
first dose of study drug.

Exclusion Criteria:

1. Has had previous exposure to approved or investigational anti-integrins (example,
natalizumab, efalizumab, etrolizumab, or AMG 181) or MAdCAM-1 antagonists, or
rituximab.

2. Has had prior exposure to vedolizumab.

3. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom
checklist prior to the administration of the first dose of study drug.

4. Requires surgical intervention for UC or CD, or is anticipated to require surgical
intervention for UC or CD during this study.

5. Use of topical (rectal) treatment with 5-ASA or corticosteroid enemas/suppositories
within 2 weeks of the administration of the first dose of study drug.

6. Has any unstable or uncontrolled cardiovascular, heart failure moderate to severe (New
York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI),
genitourinary, hematological, coagulation, immunological, endocrine/metabolic,
neurological, or other medical disorder that, in the opinion of the investigator,
would confound the study results or compromise participant safety.

7. Active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed
within 30 days of Screening or during the Screening Period that is positive, defined
as:

- Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR

- A TB skin test reaction >=5 millimeter (mm). Participants with documented
previously treated TB with a negative QuantiFERON test can be included in the
study.

8. Clinically significant current or recent history (within 1 year prior to enrollment)
of alcohol dependence or illicit drug use.

9. Has a current diagnosis of indeterminate colitis (Inflammatory bowel disease
unclassified [IBDU]). For participants less than 6 years of age, any findings that
suggest monogenic very early onset inflammatory bowel disease should be excluded.

10. Has evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.

11. Has ileostomy, colostomy, ileo-anal pouch, or known fixed symptomatic stenosis of the
intestine.

12. Has extensive colonic resection, example, subtotal or total colectomy.

13. Has a history or evidence of adenomatous colonic polyps that have not been removed.

14. Has a history or evidence of colonic mucosal dysplasia.

15. Has chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV)
infection. * HBV immune participants (that is, being hepatitis B surface antigen
[HBsAg] negative and hepatitis B antibody positive) may be included, however.

16. Has any identified congenital or acquired immunodeficiency (example, common variable
immunodeficiency, human immunodeficiency virus [HIV] infection, organ
transplantation).

17. Has evidence of or treatment for Clostridium difficile (C difficile) infection within
60 days or other intestinal pathogen within 30 days prior to first dose of study drug.

18. Has any history of malignancy, except for the following: (a) adequately treated
nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been
adequately treated and that has not recurred for at least 1 year prior to enrollment;
and (c) history of cervical carcinoma in situ that has been adequately treated and
that has not recurred for at least 3 years prior to first dose of study drug.
Participants with remote history of malignancy (example, >10 years since completion of
curative therapy without recurrence) will be considered based on the nature of the
malignancy and the therapy received, and inclusion must be discussed with the sponsor
on a case-by-case basis prior to enrollment.

19. Has a history of any major neurological disorders, including stroke, multiple
sclerosis, brain tumor, or neurodegenerative disease.

20. Has history of lupus.

21. Has had a surgical procedure requiring general anesthesia within 30 days prior to
screening or is planning to undergo major surgery during the study period.
We found this trial at
28
sites
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10467
?
mi
from
Bronx, NY
Click here to add this to my saved trials
101 Avenue du Laerbeek
Brussel, Brussels 1090
?
mi
from
Brussel,
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
(214) 456-7000
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lake Success, New York 11042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
Miami, Florida 33155
?
mi
from
Miami, FL
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Wilmington, Delaware 19803
?
mi
from
Wilmington, DE
Click here to add this to my saved trials